Blood parameters and whole-blood transcriptomics associated with immune-related adverse events in metastatic renal cell carcinoma during nivolumab plus ipilimumab
The study aims to identify blood parameters and immune profiles associated with immune-related adverse events in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Cohort study of n=51 patients with metastatic renal cell carcinoma
Analyzed pretreatment peripheral blood parameters and whole-blood transcriptomic profiles
Performed gene set enrichment analysis and CIBERSORTx evaluations to characterize immune profiles.
Higher lymphocyte (OR 14.36) and monocyte counts (OR 9.90) were linked to increased irAE risk.
Higher neutrophil counts (OR 0.08) and C-reactive protein levels (OR 0.27) correlated with decreased irAE risk.
Transcriptomic analysis showed upregulation of lymphocyte pathways and downregulation of neutrophil pathways in irAE patients.